An Italian programme for COVID-19 infection in multiple sclerosis.

Published on Jun 1, 2020in Lancet Neurology44.182
路 DOI :10.1016/S1474-4422(20)30147-2
Maria Pia Sormani83
Estimated H-index: 83
(UniGe: University of Genoa)
Sources
Abstract
Download
馃摉 Papers frequently viewed together
References2
Newest
Objective: An outbreak of 2019 novel coronavirus diseases (COVID-19) in Wuhan, China has spread quickly nationwide. Here, we report results of a descriptive, exploratory analysis of all cases diagnosed as of February 11, 2020. Methods: All COVID-19 cases reported through February 11, 2020 were extracted from China's Infectious Disease Information System. Analyses included: 1) summary of patient characteristics; 2) examination of age distributions and sex ratios; 3) calculation of case fatality a...
Source
#1Chenyu LiH-Index: 4
#2Paola Romagnani (UniFI: University of Florence)H-Index: 81
Last. Hans-Joachim AndersH-Index: 90
view all 4 authors...
Source
Cited By139
Newest
#1Alice LaroniH-Index: 24
#2Irene SchiavettiH-Index: 15
Last. Antonio UccelliH-Index: 66
view all 4 authors...
The CoronaVirus Disease 19 (COVID-19) pandemic is a threat of particular concern for people affected by chronic immune-mediated diseases, such as multiple sclerosis (MS), who are often treated with immunomodulatory and immunosuppressive drugs, which may increase the risk of infections in general. At the beginning of the COVID-19 pandemic, empirical guidelines on how to manage treatments for immune-mediated diseases, including MS, were released. Subsequently, the first clinical pictures and data ...
Source
Last. F.J. Barrero Hern谩ndez (UGR: University of Granada)
view all 3 authors...
Resumen null null Introduccion null El efecto de la infeccion por SARS-CoV-2 en los pacientes con esclerosis multiple (EM) y la influencia de los tratamientos modificadores de la enfermedad (TME) es desconocida. Hasta el momento no se ha observado que los pacientes con EM tengan mayor riesgo de infeccion por COVID-19, ni peor curso evolutivo de la misma. null null null Metodos null Estudio descriptivo de pacientes con EM e infeccion por SARS-CoV-2 diagnosticada mediante PCR. Hemos analizado vari...
Source
#1Yael Hacohen (GOSH: Great Ormond Street Hospital)H-Index: 24
#2Brenda Banwell (Children's Hospital of Philadelphia)H-Index: 71
Last. Olga Ciccarelli (UCL Institute of Neurology)H-Index: 73
view all 3 authors...
Paediatric multiple sclerosis (MS) is associated with higher relapse rate, rapid magnetic resonance imaging lesion accrual early in the disease course and worse cognitive outcome and physical disab...
Source
#1Cavid Baba (Dokuz Eyl眉l University)H-Index: 2
#2Pinar Yigit (RMIT: RMIT University)H-Index: 6
Last. Zuhal Abas谋yan谋k (RMIT: RMIT University)H-Index: 4
view all 7 authors...
Source
#1Beatriz Garcia-Ca帽ibano (Cornell University)
#2Sami Ouanes (Hamad Medical Corporation)H-Index: 2
Last. Dirk Deleu (Cornell University)H-Index: 8
view all 9 authors...
Pivotal clinical trials revealed good clinical efficiency of ocrelizumab while having a good safety profile in the management of multiple sclerosis (MS). However, real-world data of ocrelizumab in ...
Source
#1Saba Naghavi (IUMS: Isfahan University of Medical Sciences)H-Index: 1
#2Aryan Kavosh (IUMS: Isfahan University of Medical Sciences)H-Index: 1
Last. Fereshteh Ashtari (IUMS: Isfahan University of Medical Sciences)H-Index: 17
view all 8 authors...
Abstract null null Background null : Despite investigations on the effect of disease modifying therapies (DMTs) used in multiple sclerosis (MS) on coronavirus disease 2019 (COVID-19); there are still controversies. null null null Objective null : We designed this study to evaluate the epidemiological features of covid-19 in a large sample of people with MS (pwMS) in Isfahan, Iran, as well as the association between DMTs, risk of COVID-19 infection and hospitalization. null null null Methods null...
Source
#1Simona Toscano (University of Catania)H-Index: 6
#2Clara Grazia Chisari (University of Catania)H-Index: 11
Last. Francesco Patti (University of Catania)H-Index: 60
view all 3 authors...
On 11 March 2020, the World Health Organization declared the coronavirus disease 19 (COVID-19) outbreak a pandemic. In this context, several studies and clinical trials have been conducted since then, and many are currently ongoing, leading to the development of several COVID-19 vaccines with different mechanisms of action. People affected by multiple sclerosis (MS) have been considered high-risk subjects in most countries and prioritized for COVID-19 vaccination. However, the management of MS d...
Source
Abstract null null Background null In March 2020, the United Kingdom Multiple Sclerosis Register (UKMSR) established an electronic case return form, designed collaboratively by MS neurologists, to record data about COVID-19 infections in people with MS (pwMS). null null null Objectives null Examine how hospital admission and mortality are affected by disability, age and disease modifying treatments (DMTs) in people with Multiple Sclerosis with COVID-19. null null null Methods null Anonymised dat...
Source
#1Ahya Ali (UM: University of Michigan)H-Index: 1
#2Deanna Dwyer (UM: University of Michigan)H-Index: 1
Last. Yang Mao-Draayer (UM: University of Michigan)H-Index: 12
view all 9 authors...
Little is known about COVID-19 mRNA vaccine humoral immune responses in patients with central nervous system autoimmune demyelinating diseases, multiple sclerosis (MS) and neuromyelitis optica (NMO), who are on B-cell depleting therapies (BCDT) and other disease modifying therapies (DMTs). We conducted a single center prospective study to identify the clinical and immunological features associated with vaccine-induced antibody response in 53 participants before and after COVID-19 mRNA vaccinatio...
Source
#1Tobias Zrzavy (Medical University of Vienna)H-Index: 11
#2Isabella Wimmer (Medical University of Vienna)H-Index: 15
Last. Thomas Berger (Medical University of Vienna)H-Index: 10
view all 4 authors...
The outbreak of the SARS-CoV-2 pandemic with an until then unknown, infectious agent posed unprecedented challenges to health care systems and unmasked their vulnerability and limitations worldwide. Patients with long-term immunomodulatory/suppressive therapies, as well as their physicians, were and are concerned about balancing the risk of infection and disease-modifying effects. Over the last few months, the knowledge regarding SARS-CoV-2 has been growing tremendously, as well as the first exp...
Source
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.